Probiotic Composition for Ulcerative Colitis Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for ulcerative colitis lack specificity and efficacy, with existing medications causing side effects and not addressing the underlying inflammatory issues effectively, and there is a need for a safe and effective medicament for inflammation-related diseases.

Innovation Solution

A composition comprising Megamonas funiformis AF24-28AC and Anaerofustis stercorihominis AM25-6, along with other beneficial bacteria such as Collinsella shenzhenensis, Roseburia inulinivorans, Butyribacter intestini, Lactobacillus gasseri, and Lactobacillus acidophilus, which improves intestinal microecology and forms a protective barrier to prevent or treat inflammation and related diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If salicylic acids are used to treat ulcerative colitis, then inflammatory response is alleviated, but side effects such as gastrointestinal reactions, liver toxicity, and bacterial flora disorders occur

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of conventional anti-inflammatory drugs by using probiotics that naturally produce anti-inflammatory substances. The beneficial bacteria (Megamonas funiformis, Anaerofustis stercorihominis, etc.) produce short-chain fatty acids and other metabolites that inhibit inflammation without causing the harmful side effects of chemical drugs, thus transforming a harmful treatment approach into a beneficial one.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces beneficial bacteria as intermediary substances that mediate the treatment effect. These probiotics act as intermediaries between the patient and the inflammatory condition, producing natural anti-inflammatory compounds that alleviate symptoms without directly interfering with the patient's body systems in a harmful way, unlike conventional drugs.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If adrenal glucocorticoids are used for severe UC patients, then inflammation is controlled effectively, but metabolic disorders and water retention occur

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoidmetabolic disorders

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent replaces the harmful metabolic side effects of glucocorticoids with beneficial metabolic products from probiotics. The bacteria produce short-chain fatty acids and other metabolites that naturally control inflammation while having no adverse metabolic effects, thus converting a treatment with harmful byproducts into one with beneficial outcomes.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If immunosuppressive agents are used to inhibit T cell IL-2 generation, then ulcerative colitis progress is affected, but nephrotoxicity and secondary infection occur

Engineering Contradiction:

Improveimmune response inhibitionVSAvoidnephrotoxicity and secondary infection

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effects of immunosuppressive drugs by using probiotics that naturally modulate immune response. The beneficial bacteria produce metabolites that inhibit inflammation and prevent disease progression without suppressing the immune system to the extent that causes nephrotoxicity or secondary infections, thus transforming a harmful immune intervention into a beneficial natural modulation.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

4Duration of action of moving object

If conventional medicines are used for ulcerative colitis, then inflammation is alleviated temporarily, but the disease cannot be cured and drug resistance develops

Engineering Contradiction:

Improveduration of inflammation alleviationVSAvoidcure capability

Core Design Contradiction:

Duration of action of moving objectVSReliability

Solution Approach 1:

The patent introduces probiotics that continuously produce anti-inflammatory metabolites, providing sustained treatment effect. The beneficial bacteria maintain their protective action over time, continuously producing short-chain fatty acids and other anti-inflammatory substances that prevent disease progression and promote long-term remission, thus transforming temporary symptom relief into continuous therapeutic action.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The patent converts the limitation of conventional drugs that cause bacterial flora disorders into a benefit by using probiotics that restore and maintain healthy gut microbiota. The beneficial bacteria not only provide anti-inflammatory effects but also strengthen the natural protective barrier of the gut, preventing drug resistance and promoting long-term disease freedom.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively prevents or treats ulcerative colitis and other intestinal microecology-related diseases by promoting a beneficial bacterial barrier, reducing disease activity index, and controlling weight loss without significant side effects or drug resistance.

Implementation Method 1

Megamonas funiformis and Anaerofustis stercorihominis can improve the intestinal microecology in the human body, forming a microecology-protective barrier composed of beneficial bacteria

Methodology Applied

Scientific EffectProbiotic effect:

Implementation Method 2

metabolites generated by Megamonas funiformis and Anaerofustis stercorihominis can be served as probiotic materials, which promote the prevention or treatment on inflammation or inflammation-related diseases

Methodology Applied

Scientific EffectMetabolite production: Fermentation

Data Source

PatentEP3808357B1Composition comprising megamonas funiformis and anaerofustis stercorihominis and use thereof

Publication Date: 2025.03.26 SHENZHEN HUADA GENE INST

Figure 1~2

AI summary

Provided are a composition and the uses thereof. Said composition comprises Megamonas funimormis and/or a metabolite thereof, as well as Anaerofustis stercorihominis and/or a metabolite thereof. Said composition can efficiently treat and prevent inflammation, specifically ulcerative colitis, and related diseases thereof by using a combination of Megamonas funimormis and Anaerofustis stercorihominis, and is safe, efficient, exhibits low toxicity and does not easily produce resistance.